Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced inducement grants to 35 new employees. The Compensation Committee approved nonstatutory stock options to purchase 646,700 shares of common stock under the company's 2023 Inducement Option Plan.
The stock options have an exercise price of $6.02 per share, matching the closing price on August 1, 2025. These options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months, contingent on continued employment.
Kura Oncology (Nasdaq: KURA), un'azienda biofarmaceutica in fase clinica specializzata in terapie di precisione per il trattamento del cancro, ha annunciato concessioni di incentivi a 35 nuovi dipendenti. Il Comitato per la Remunerazione ha approvato opzioni azionarie non statutarie per l'acquisto di 646.700 azioni ordinarie nell'ambito del Piano di Opzioni di Incentivazione 2023 dell'azienda.
Le opzioni azionarie hanno un prezzo di esercizio di 6,02 $ per azione, corrispondente al prezzo di chiusura del 1° agosto 2025. Queste opzioni matureranno in un arco di quattro anni, con il 25% che matura dopo un anno e il restante saldo che matura mensilmente nei successivi 36 mesi, subordinatamente alla permanenza in servizio.
Kura Oncology (Nasdaq: KURA), una empresa biofarmacéutica en etapa clínica enfocada en medicamentos de precisión para el tratamiento del cáncer, ha anunciado concesiones de incentivos a 35 nuevos empleados. El Comité de Compensación aprobó opciones sobre acciones no estatutarias para comprar 646,700 acciones ordinarias bajo el Plan de Opciones de Incentivos 2023 de la compañía.
Las opciones sobre acciones tienen un precio de ejercicio de $6.02 por acción, igualando el precio de cierre del 1 de agosto de 2025. Estas opciones se consolidarán durante cuatro años, con un 25% consolidándose después de un año y el saldo restante consolidándose mensualmente durante 36 meses, condicionado a la continuidad laboral.
Kura Oncology (나스닥: KURA)는 암 치료를 위한 정밀 의약품에 중점을 둔 임상 단계의 생명공학 제약 회사로, 35명의 신규 직원에게 유인 보상을 발표했습니다. 보상 위원회는 회사의 2023년 유인 옵션 계획에 따라 646,700주의 보통주를 매수할 수 있는 비법정 주식 매수선택권을 승인했습니다.
주식 매수선택권의 행사가격은 주당 6.02달러로, 2025년 8월 1일 종가와 동일합니다. 이 옵션은 4년에 걸쳐 권리가 부여되며, 25%는 1년 후에, 나머지 75%는 36개월 동안 매월 부여되며 계속 근무 조건이 필요합니다.
Kura Oncology (Nasdaq : KURA), une société biopharmaceutique en phase clinique spécialisée dans les médicaments de précision pour le traitement du cancer, a annoncé des attributions d'incitations à 35 nouveaux employés. Le comité de rémunération a approuvé des options d'achat d'actions non statutaires pour acquérir 646 700 actions ordinaires dans le cadre du plan d'options d'incitation 2023 de l'entreprise.
Le prix d'exercice des options est de 6,02 $ par action, correspondant au cours de clôture du 1er août 2025. Ces options seront acquises sur une période de quatre ans, avec 25 % acquis après un an et le solde restant acquis mensuellement sur 36 mois, sous réserve de la poursuite de l'emploi.
Kura Oncology (Nasdaq: KURA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Präzisionsmedikamente zur Krebsbehandlung spezialisiert hat, hat Zuwendungen an 35 neue Mitarbeiter angekündigt. Der Vergütungsausschuss genehmigte nichtstatutarische Aktienoptionen zum Kauf von 646.700 Stammaktien im Rahmen des Inducement-Optionsplans 2023 des Unternehmens.
Die Aktienoptionen haben einen Ausübungspreis von 6,02 $ pro Aktie, entsprechend dem Schlusskurs vom 1. August 2025. Diese Optionen werden über vier Jahre vesten, wobei 25 % nach einem Jahr und der verbleibende Rest monatlich über 36 Monate vesten, vorausgesetzt die Beschäftigung wird fortgesetzt.
- None.
- Potential dilution from 646,700 new stock options
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on August 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 646,700 shares of common stock to thirty-five (35) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
What inducement grants did Kura Oncology (KURA) announce on August 4, 2025?
How will the stock options vest for Kura Oncology's new employees?
What is the exercise price for Kura Oncology's inducement stock options granted in August 2025?
How many new employees received stock options from Kura Oncology in August 2025?
